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Myelofibrosis (MF) is a clonal stem cell disorder charac-
terized by bone marrow fibrosis, extramedullary hemat-
opoiesis, and an increased risk of transformation to 
acute leukemia. Myelofibrosis may develop as a primary 
manifestation of MPNs (PMF) or develop from a pre- 
existing condition of polycythemia vera (PPV- MF) or 
essential thrombocythemia (PET- MF). A variable degree 
of leukocytosis and thrombocytosis associated with sple-
nomegaly and progressive bone marrow fibrosis leading 
to extramedullary hematopoiesis and finally to cytope-
nias are the main clinical characteristics of primary 
myelofibrosis.
In 2005, the V617F mutation of Janus kinase 2 (JAK2) 
was discovered [1]. The mutation leads to constitutive 
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Abstract
The Wilms tumor gene WT1 is a useful marker of clonal hematopoiesis and 
it has been shown to be a good marker of residual disease and it reflects the 
response to therapy. Although myelofibrosis is characterized by mutations of 
JAK2 and calreticulin (CALR), these mutations are not useful to monitor  response 
to therapy. In this study we demonstrated that in patients affected by myelofi-
brosis WT1 correlates with the International Prognostic Scoring System (IPSS) 
score at diagnosis. Furthermore WT1 is a good marker of response to JAK2 
inhibitors especially for patients without blasts and for patients who develop 
anemia or thrombocytopenia not for progression but as therapy related toxicity. 
Finally, WT1 transcript reduction can mirror a benefit of therapy on the disease 
burden. This study demonstrated that WT1 is a good marker for monitoring 
the response to therapy in patients affected by myelofibrosis.
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activation of JAK2 and contributes to deregulate JAK 
signaling in myelofibrosis (MF), polycythemia vera (PV), 
and essential thrombocythemia (ET). This finding gener-
ated the illusion of facing a disease with one initiating 
mutation and possibly a useful drugable target. More 
recently, two groups identified somatic mutations in exon 
9 of calreticulin (CALR) encoding the endoplasmic reticu-
lum chaperone calreticulin in about 70–80% of JAK2 
unmutated myelofibrosis and ET [2]. In addition, the 
MPL mutations are identified in 10% of JAK2V617F nega-
tive, CALR negative myelofibrosis.
The identification of the JAK2V617F mutation led to the 
development of JAK inhibitors, small molecules that selec-
tively target JAK signaling, for the treatment of MPN 
patients. It was shown in phases II and III clinical trials 
that ruxolitinib is effective in the reduction of spleen size 
and disease- related symptoms. Ruxolitinib is now approved 
in the United States and Europe for the treatment of 
myelofibrosis. Several additional compounds are at different 
stages of clinical development. While most patients with 
myelofibrosis benefit from ruxolitinib therapy, many of 
them are resistant or obtain a suboptimal response or 
loose the response during therapy. Recently, Patel and 
colleagues demonstrated that the number of mutations 
may have impact on the response to therapy and finally 
on overall survival. By contrast, Guglielmelli and colleagues 
did not find any correlation between mutations and 
responses. Ruxolitinib has been shown to have limited 
effect on granulocytic JAK2V617F mutant load [3]. A mod-
est reduction of the JAK2V617F allele burden (8% from 
baseline at 72 weeks) was observed in MF patients in the 
COMFORT- II study. More recently in a phase III study, 
a reduction in allele burden from baseline was observed 
and correlated with ruxolitinib treatment response, in par-
ticular with reduction in symptoms and spleen volume.
Despite this, the correlation between JAK2V617F allele 
burden and response to treatment is still controversial. 
Based on the available data, JAK2V617F cannot be considered 
a molecular marker of residual disease or drug response.
In the absence of molecular marker, the response is com-
monly evaluated based on the IWG- MRT criteria, recently 
updated by the European Leukemia Net (ELN) [4]. The 
criteria of complete response include the achievement of a 
normocellular bone marrow (BM), less than 5% of blasts, 
and a reduction of fibrosis to less than grade 1. In peripheral 
blood, the achievement of the complete response is based 
on the achievement of the Hb level higher than 10 g/dL, 
neutrophil count higher than 1 × 109/L, and platelets more 
than 100 × 109/L and less than 2% of immature cells. In 
addition, reduction in spleen volume and resolution of symp-
toms are requested to classify the response as complete.
Based on these criteria it is difficult to assess the response 
to JAK2 inhibitors mainly because of the drug- related 
cytopenia. The clinical response and the BM parameters 
are usually considered to evaluate JAK2 inhibitors response. 
For patients without an increase of blast cells in the bone 
marrow and peripheral blood is cumbersome to establish 
the efficacy of ruxolitinib in controlling the disease. The 
clinical response and the symptoms assessment are not 
reliable markers of disease control. Therefore, for many 
patients affected by primary or secondary myelofibrosis, a 
molecular marker of response to therapy is still lacking.
The Wilms’ tumor (WT1) gene has been demonstrated 
to be a sensitive molecular marker in acute leukemias, 
myelodysplastic syndromes, and myeloproliferative disor-
ders. It is now broadly accepted as marker of minimal 
residual disease after chemotherapy and bone marrow 
transplantation in acute leukemias [5].
After written informed consent, BM samples were col-
lected from 54 patients affected by myelofibrosis (28 were 
PMF, 18 PPV- MF, and 8 PET- MF). In 32 patients, BM 
and PB samples are available during follow- up. A median 
of five samples are available for each patient, the median 
time of follow- up is 28 months (range 12–56).
All the patients were characterized at the molecular 
level for the presence of JAK2, CALR, and MPL muta-
tions and for cytogenetic analysis. Of the 54 patients, 32 
patients have been treated with ruxolitinib. Ten patients 
experienced leukemic transformation during follow- up.
WT1 has been analyzed in all the patients at diagnosis 
and during follow- up as previously described [5]. We did 
not find any significant correlation between WT1 gene 
expression and JAK2 or CALR mutations or cytogenetic 
abnormalities.
As shown in Figure 1A, WT1 expression levels strictly 
correlate with the International Prognostic Scoring System 
(IPSS) at diagnosis. In addition, as already demonstrated 
in acute leukemias, there is a strict correlation between 
WT1 at diagnosis in BM and PB samples (Fig. 1B). The 
possibility to monitor the disease in PB allows to perform 
a strict follow- up and, importantly in myelofibrosis, it 
allows to overcome the limit of “punctio sicca” which is 
a common obstacle to disease evaluation.
In patients who respond to ruxolitinib in terms of 
reduction in spleen and symptoms, WT1 progressively 
decreases, but more importantly, the reduction of WT1 
transcript parallels the reduction of fibrosis and of blast 
cells (example in Fig. 1C).
To establish the role of WT1 as marker of disease, 
we followed patients during disease progression and found 
a progressive and significant increase of WT1 that started 
a median of 3 months before leukemic transformation 
(range 1–7) when the blood parameters were stable. 
(Fig. 1C and D). In half of the patients who progressed 
to leukemia, WT1 increased several months before when 
no other signs of transformation were present in bone 
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marrow, in particular no evident increase of blast cells 
were detected. In those patients, WT1 was the only 
parameter which allowed to predict the progression.
To give further strength to these findings, we followed 
12 patients who developed significant thrombocytopenia 
or anemia for drug- related toxicity, but who did not 
progress after a median of 3.2 years of follow- up from 
the hematological toxicity. In all these patients, WT1 
transcript never increased from baseline.
Based on these data, WT1 is a useful marker of disease 
and of response to JAK2 inhibitors especially for patients 
without blasts and for patients who develop anemia or 
thrombocytopenia not for progression but as therapy- 
related toxicity. Finally, WT1 transcript reduction can 
mirror a benefit of therapy on the disease burden even 
in the absence of spleen reduction or of improvement 
of symptoms score. Finally, the possibility to monitor the 
disease even in PB offers the opportunity to perform a 
strict follow- up with a better compliance of both, patients 
and clinicians, and to overcome the obstacle due to the 
failure of the bone marrow aspirate in patients affected 
by myelofibrosis.
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Figure 1. (A) WT1 expression (WT1 copies/104 ABL copies) according to the International Prognostic Scoring System (IPSS) risk group. (B) Correlation 
between WT1 gene expression in BM and PB (r = 0.85). (C) Example of WT1 expression during follow- up of a patient treated with ruxolitinib. After 
1 year of therapy the patient responded with a reduction of BM fibrosis from grade III (GIII) to grade II (GII). After 20 months of therapy WT1 started 
to increase and after 24 months leukemic transformation (LT) was observed. (D) Example of WT1 expression during follow- up of a patient treated 
with ruxolitinib. After 6 months of therapy blast cells (BC) were 2%, after 24 months the blast cells were 5%, and WT1 increased in parallel with the 
number of blast cells. After 28 months there was a further increase in WT1 associated with leukemic transformation (LT). * P < 0.05; ** P < 0.01; 
*** P < 0.001.
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